Protocol Ledger

NCT06685757 · Phase III · ACTIVE NOT RECRUITING

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Interventional Phase III clinical trial protocol NCT06685757 sponsored by Biogen in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-03 Enrollment: 132 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06685757
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)132 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06685757
Protocol FieldVerified Registry Value
NCT IdentifierNCT06685757
Consolidated Lead SponsorBiogen
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment132 participants (ACTUAL)
Registered Start Date2024-12-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI